ProteoGenix is offering 20% off their cell-related services until the end of the year. Continue reading to to learn how to take advantage of this promotion.

About ProteoGenix

ProteoGenix takes pride in significantly enhancing the success rate of biomolecules advancing to the Investigational New Drug (IND) application stage. Functioning as a comprehensive service integrator, ProteoGenix assists their clients throughout the entire journey from early discovery to clinical development. Their primary focus is on anticipating the future needs of biomolecules right from the outset and devising an appropriate development strategy. This involves offering a diverse array of cutting-edge solutions and technologies. With over 15 years of expertise and a robust international reputation, they provide exclusive and tailored access to six interconnected service areas: Antibody Engineering (Humanization, Bi-specific, ADC, affinity maturation, molecule optimization), Bioprocess Development (IP-free stable cell line development, fermentation, and bioreactor production optimization), Monoclonal and Polyclonal Antibody Development (Hybridoma method and Phage Display), Recombinant Protein and Antibody Production (E. coli, B. subtilis, Yeast, Insect cells, Mammalian cells), Gene Synthesis , and Peptide Synthesis .

Year-End Discount

ProteoGenix is extending Scientist.com clients a 20% off discount on their B-cell sorting, Hybridoma development, and Stable cell line generation services until December 31, 2023. Be sure to include ProteoGenix in your request here .

B-cell sorting provides highly affine antibodies with natural VH and VL pairing and maximum B-cell diversity. Hybridoma development provides solutions for both therapeutic and diagnostic applications, with immunization strategies ranging from protein, peptide to DNA. Stable cell line generation is ProteoGenix’s new solution for single cell seeding and in-well verification by VIPS™. Request more information to learn more about each of these services.